Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

TMS acelerado para la depresión perinatal (PAiNT)

15 de septiembre de 2026 actualizado por: Joseph J. Taylor, MD, PhD, Brigham and Women's Hospital

Terapia de neuromodulación ITB acelerada perinatal

We are studying a treatment for depression called accelerated Transcranial Magnetic Stimulation (TMS) among pregnant and postpartum individuals. TMS is a focal, non-invasive form of brain stimulation that is cleared by the Food and Drug Administration for depression. Typically, traditional TMS involves daily treatments for 6-8 weeks. In this study, we will offer an accelerated form of TMS that involves multiple daily treatments for 5 days.

Descripción general del estudio

Descripción detallada

Perinatal depression is underdiagnosed, undertreated, and understudied. Approximately one in five individuals will experience perinatal depression, which spans from conception to one year after birth. Untreated perinatal depression increases the risk of stillbirth, preterm birth, substance abuse, parental suicide, and developmental delay. There are limited empirical data to guide treatment of perinatal depression. Psychotherapy can be effective for mild-to-moderate depression, but it is slow acting and difficult to access. Antidepressants show inconsistent benefits and safety; moreover, patients report feeling anxious or guilty about taking them.

Transcranial magnetic stimulation (TMS) is FDA cleared treatment for major depressive disorder, adolescent depression, late life depression, and anxious depression. It has also shown promise as a safe and effective biological intervention for perinatal depression for both the mother and fetus. One of the most exciting new developments in neurostimulation is accelerated intermittent theta burst stimulation (iTBS), a TMS protocol that involves multiple daily treatments rather than once daily treatment. A specific accelerated TMS protocol called Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT) was FDA cleared in September 2022 because of its rapid and robust antidepressant effects. In an open-label study (n=21), SNT significantly reduced depression in one day and yielded 90.5% remission after five days. Importantly, there is no evidence that accelerated TMS protocols pose more risk than conventional TMS protocols that have a strong safety profile.

While SNT is a potential breakthrough treatment, it has not been tested in peripartum individuals. Accelerated iTBS may expedite depressive symptom improvement and reduce the need for pharmacotherapy for individuals struggling with perinatal depression. If tolerable and efficacious, this treatment modality may increase the viable treatment options available to peripartum women with depressive symptoms.

In this pilot trial, patients who are currently pregnant or postpartum with treatment-resistant depression (n=12) will receive a modified SNT with neuronavigation. Treatment site location will be guided by MRI when possible given the promising internal findings highlighted above. However, if neuroimaging is not chosen by the patient, unsafe for the patient for any reason, or not tolerable for the patient, we will offer treatment with scalp-based measurement (i.e., TMS targeting based on Beam F3 method). Overall, this study is critically important for informing the viability of future accelerated iTBS trials in a peripartum population and may shape the future of affective treatment options in this patient group.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

24

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: Interventional Psychiatry Research Group
  • Número de teléfono: 617 525 3536
  • Correo electrónico: mgbpaint@mgb.org

Ubicaciones de estudio

    • Massachusetts
      • Boston, Massachusetts, Estados Unidos, 02115
        • Reclutamiento
        • Brigham and Women's Hospital
        • Contacto:
          • Interventional Psychiatry Research Group
          • Número de teléfono: 617 525 3536
          • Correo electrónico: mgbpaint@mgb.org
        • Investigador principal:
          • Joseph J Taylor, MD, PhD

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años a 55 años (Adulto)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Femenino

Descripción

Inclusion Criteria:

  • Age 18-55
  • All individuals must be 14-34 weeks gestational age or within one year of delivery at the time of treatment. The odds of delivery nears 10% after 36 weeks, which would limit participants from being able to complete the study and interfere with the primary study aim to understand safety and tolerability. Additionally, after 36 weeks, the standard of care is weekly obstetric check-in visits, which would be challenging for patients to complete given the time demands of the study protocol.
  • Patients will not be scanned after 32 weeks gestational age due to the time needed to construct the individualized treatment target. Individuals seeking treatment beyond 32 weeks will be offered scalp-based target localization so as not to limit patient access to care.
  • English proficiency sufficient for informed consent, questionnaires/tasks, and treatment
  • Primary diagnosis of major depressive disorder per DSM-V criteria (MINI International Neuropsychiatric Interview/ Structured Clinical Interview for DSM-5): >20 on the Montgomery-Åsberg Depression Rating Scale (MADRS) and moderate to severe level of treatment resistance (Maudsley Staging Method)
  • Stable antidepressant medication regimen, or remain medication free, for 4 weeks prior to treatment and to remain on this regimen throughout the treatment course. We request that this regimen remain stable until the 1 month post-treatment if clinically appropriate.
  • Primary clinician (e.g. psychiatrist, therapist, psychologist, APRN, PA, etc.) responsible for psychiatric care before, during, and after the trial in addition to an obstetric provider responsible for obstetric care.
  • Agreement to lifestyle considerations: Continue usual intake patterns of caffeine- or xanthine-containing products (e.g. coffee, tea, soft drinks, chocolate) throughout treatment

Exclusion Criteria:

  • Concurrent use of rapid acting antidepressant agent (ketamine/esketamine/ECT)
  • Receiving or planning to receive other TMS treatments during course of participation
  • Obstetric concerns: Preeclampsia and/or current frequent, painful contractions (more than one every 10 minutes)
  • History of: Neurosurgical intervention for depression, autism spectrum disorder, intellectual disability, severe cognitive impairment, significant neurological illness (e.g., dementia, Parkinson's, Huntington's, brain tumor, seizure disorder, subdural hematoma, multiple sclerosis, brain lesion), untreated or insufficiently treated endocrine disorder, and/or treatment with investigational drug or intervention during the study period
  • ≥ 30% change in MADRS score between screening and baseline
  • Anyone presenting with: Mania or hypomania, psychosis, active suicidal ideation with plan and some intent to act or a suicide attempt (defined by C-SSRS) within the past 3 months, neurological lesion, contraindications to either TMS or MRI (e.g., metallic implants, severe insomnia > 4 hours per night with hypnotic, etc.), and/or current moderate or severe substance use disorder or demonstrating signs of acute substance withdrawal
  • Existing tinnitus (ringing in the ears) that causes functional impairment
  • History of retinal detachment or other retinal pathology
  • Severe borderline personality disorder
  • Any other condition deemed by the PI to interfere with the study or increase risk to the participant

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Otro
  • Asignación: N / A
  • Modelo Intervencionista: Asignación de un solo grupo
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Open-label aiTBS for pregnant/postpartum individuals

10 iTBS treatment sessions per day (18,000 pulses/day) for 5 consecutive days (90,000 pulses total) to the dorsolateral prefrontal cortex (DLPFC). In the unlikely event that a participant is late for an hourly treatment, then the treatment will be delayed accordingly. The minimum gap between treatments will be 25 minutes. Each iTBS treatment will consist of 60 cycles of 10 bursts of three pulses at 50 Hz delivered in 2-second trains (5 Hz) with an 8-second intertrain interval. Stimulation will be delivered at 90% resting motor threshold (rMT), adjusted for depth of the identified functional connectivity target or based on traditional scalp measurements.

Non-invasive form of brain stimulation.

Otros nombres:
  • TMS
  • aiTBS
  • Estimulación de ráfaga theta intermitente acelerada

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Tolerability as measured by ratings of the Client Satisfaction Questionnaire (CSQ-8)
Periodo de tiempo: 1 month after treatment

The CSQ-8 asks individuals about their overall experience with aTMS.Higher scores indicate a greater level of tolerability. We hypothesize that participants will report high levels of treatment satisfaction (>24) on the Client Satisfaction Questionnaire (CSQ-8).

The primary outcome will be a composite defined as meeting 3 out of 4 metrics listed here.

1 month after treatment
Acceptability as measured by percentage of individuals who complete an entire treatment course
Periodo de tiempo: 1 month after treatment

Higher percentage of individuals who completed an entire course (i.e., 50 treatments) indicates higher acceptability. We hypothesize that 9/12 participants will complete at least 75% of treatments.

The primary outcome will be a composite defined as meeting 3 out of 4 metrics here.

1 month after treatment
Safety as measured by reports of adverse events
Periodo de tiempo: 1 month after treatment

We will monitor and report the rate of serious adverse events, including maternal seizures in the sample. We hypothesize that there will be no serious adverse events.

1 month after treatment
Feasibility as measured by the number of individuals treated throughout the study
Periodo de tiempo: From the beginning to the end of the study

Report of the number of individuals who received treatment throughout the entire study (i.e., approximately 2 years). We hypothesize that we will be able to enroll and treat 12 participants in two years.

The primary outcome will be a composite defined as meeting 3 out of 4 metrics here.

From the beginning to the end of the study

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Montgomery-Åsberg Depression Rating Scale (MADRS)
Periodo de tiempo: From baseline to 1 month post treatment.

A clinician rated tool used to assess the severity of depression in adults. The MADRS consists of 10 items, each scored on a 7 point scale 0-6 with higher scores indicating more severe depressive symptoms.

From baseline to 1 month post treatment.
Assess the effects of accelerated TMS on birth outcomes and lactation
Periodo de tiempo: Throughout the 5 days of treatment to 1 month post treatment

We will monitor and report neonatal APGAR scores from infants delivered from mothers in the sample, birth weights, intradelivery maternal pain scores, birth modality (e.g. vaginal or C-section), and maternal blood loss. For individuals postpartum, we will ask participants to log their milk supply daily during treatment to determine any effects

Throughout the 5 days of treatment to 1 month post treatment

Otras medidas de resultado

Medida de resultado
Medida Descripción
Periodo de tiempo
Beck Depression Inventory (BDI)
Periodo de tiempo: Before treatment, daily throughout treatment, 2 week post treatment, and 1 month post treatment

Depression severity rating scales (0-63, higher numbers indicate higher severity)

Before treatment, daily throughout treatment, 2 week post treatment, and 1 month post treatment
Beck Anxiety Inventory (BAI)
Periodo de tiempo: Before treatment, daily throughout treatment, 2 week post treatment, and 1 month post treatment

Anxiety severity rating scale (0-63, higher numbers indicate higher severity)

Before treatment, daily throughout treatment, 2 week post treatment, and 1 month post treatment
Young Mania Rating Scale (YMRS)
Periodo de tiempo: Before treatment, daily throughout treatment, 2 week post treatment, and 1 month post treatment

11 item scale evaluating mania. Scored 0-60. Higher score indicates worse outcome/higher mania

Before treatment, daily throughout treatment, 2 week post treatment, and 1 month post treatment
Edinburgh Postnatal Depression Scale
Periodo de tiempo: Before treatment, 2 weeks after treatment, and 1 month after treatment.

A scale created to help identify women who may be suffering from postpartum depression. Each question is scored 0-3, with a maximum score of 30. A score of more than 10 suggests minor or major depression may be present.

Before treatment, 2 weeks after treatment, and 1 month after treatment.
Hamilton Rating Scale for Depression
Periodo de tiempo: Before treatment, 2 weeks after treatment, and 1 month after treatment.

Designed to rate the severity of depression in individuals. Scores range from 0-52, a higher score indicating more severe depression.

Before treatment, 2 weeks after treatment, and 1 month after treatment.

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

5 de agosto de 2025

Finalización primaria (Estimado)

1 de julio de 2027

Finalización del estudio (Estimado)

1 de julio de 2028

Fechas de registro del estudio

Enviado por primera vez

2 de mayo de 2025

Primero enviado que cumplió con los criterios de control de calidad

5 de mayo de 2025

Publicado por primera vez (Actual)

13 de mayo de 2025

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

18 de septiembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

15 de septiembre de 2026

Última verificación

1 de agosto de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

INDECISO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

Sí

producto fabricado y exportado desde los EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir